Welcome to Scandinavian Biopharma,

We are an entrepreneurial company specialised in global vaccine development, manufacturing, registration and commercialization of biopharmaceutical products. Our team has previously successfully developed, manufactured, registered and globally l[...]

Turning ETEC Vaccine Development into Real Impact - Together with EDCTP

Developing a vaccine against ETEC in young children has long been a global health challenge. We are now closer than ever to changing that. At Scandinavian Biopharma, we are advancing what could become the world’s first vaccine to protect yo[...]

Scandinavian Biopharma Announces Publication of ETVAX® Phase 2b Data in The Lancet Infectious Diseases and Confirms Phase 3 Readiness

Scandinavian Biopharma today announces that the comprehensive results from its Phase 2b trial of ETVAX®, the lead oral vaccine candidate against enterotoxigenic Escherichia coli (ETEC), have been published in The Lancet Infectious Diseases, one[...]